What Is Pulmonary Arterial Hypertension? Causes, Symptoms, and Treatments to Know
Key takeaways:
Pulmonary arterial hypertension (PAH) occurs when the small blood vessels in your lungs narrow. This leads to increased blood pressure in your lungs, called pulmonary hypertension.
PAH can cause symptoms like fatigue, shortness of breath, and dizziness. Over time, PAH can lead to heart failure.
Medications for PAH can help reduce symptoms and slow disease progression. Some people with PAH may be eligible for a lung transplant.
Table of contents
Pulmonary arterial hypertension (PAH) is a rare type of pulmonary hypertension, which is high blood pressure in the lungs. PAH happens when the small blood vessels in your lungs become stiff and narrow, making it difficult for blood to pass through.
As a result, your heart must work harder to push blood into your lungs. This increases the blood pressure in your pulmonary arteries. Over time, PAH worsens and can eventually lead to heart failure. But there are treatments that can slow these effects and improve symptoms.
What are the symptoms of pulmonary arterial hypertension?
People with PAH often have no symptoms at first. Early symptoms include shortness of breath or lightheadedness during exercise. As PAH advances, you may notice symptoms like:
Shortness of breath
Dizziness or fainting
Swelling in your legs
It’s important to note that PAH is very rare. And there are other, more common, medical conditions that can also cause these symptoms.
What causes pulmonary arterial hypertension?
There are many reasons why people develop PAH:
Genetics: PAH can be caused by gene mutations that lead to stiffening of the pulmonary arteries. People can inherit these genetic mutations from their parents. This type of PAH runs in families.
Medications and substances: Some medications used to treat cancer, like dasatinib and mitomycin-C, can lead to PAH. Methamphetamine use can also cause PAH.
Medical conditions: Some medical conditions increase your risk of developing PAH. These include connective tissue disorders, human immunodeficiency virus (HIV), portal hypertension from cirrhosis, and some types of congenital heart disease.
Pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH): These are two rare causes of PAH. PVOD is when blood clots and scar tissue form in the veins of your lungs. PCH occurs when too many small blood vessels grow in your lungs.
What are your treatment options for PAH? Learn about the different types of PAH medications and how they stack up against each other.
Adempas side effects: Our experts review Adempas’ side effects and how to manage them.
Is portable oxygen therapy right for you? Learn more about how portable oxygen can help ease shortness of breath on the go.
Sometimes it’s not clear why someone develops a medical condition. These cases are called “idiopathic.” Almost half of people with PAH have idiopathic PAH. This means many people with PAH never find how or why they developed the condition.
How is pulmonary arterial hypertension diagnosed?
Pulmonary arterial hypertension can take time to diagnose. If you have symptoms of PAH, your healthcare team may ask you to start with lung function tests, blood tests, or a CT scan of the lungs to help rule out other common causes of shortness of breath, like asthma, COPD, or anemia.
More specialized testing for PAH includes:
Electrocardiogram (ECG), which is a test that can be performed in your doctor’s office. An ECG shows the electrical conduction in your heart. It can also show evidence of structural changes in your heart that could be caused by higher than normal blood pressures in your lungs.
Echocardiogram (TTE), which is an ultrasound of your heart that looks at the size of your heart chambers and your heart’s pumping power. During this test the pressure inside different parts of your heart can be estimated.
Cardiac catheterization, which is where a catheter is inserted into a blood vessel in your arm or leg and moved into your heart. This allows for direct measurement of the pressure inside the heart chambers.
PAH is diagnosed when both of the following are true:
The pressure inside your pulmonary arteries is high
The increased pressure isn’t caused by problems in the left side of your heart, chronic lung disease, or blood clots in your lungs
How is pulmonary arterial hypertension treated?
PAH is treated with medication to lower blood pressure in your lungs. Treatment for PAH may include:
Calcium channel blockers: Medications like amlodipine and diltiazem are commonly used for hypertension (high blood pressure). They can also lower blood pressure in the arteries inside your lungs.
Endothelin antagonists: Endothelin antagonists block the activity of endothelin, a substance that causes your blood vessels to narrow. Endothelin antagonists like ambrisentan and bosentan, have the opposite effect. They keep your blood vessels dilated (open) and lower blood pressure in your lungs.
Phosphodiesterase 5 (PDE5) inhibitors: PDE5 inhibitors are a group of medications that help relax blood vessels. PDE5 inhibitors, like sildenafil and tadalafil, help treat PAH.
Guanylate cyclase stimulators: Riociguat is a medication that helps dilate blood vessels in your lungs. Studies show that riociguat can help lower pulmonary artery pressure and reduce shortness of breath in people with PAH.
Prostacyclin analogues and prostacyclin receptor agonists: Prostacyclins cause blood vessels to dilate and prevent formation of small blood clots. Medications like treprostinil and selexipag act like prostacyclin in your body and help treat PAH.
Diuretics: Diuretics (water pills) help remove extra fluid from your body. Diuretics like furosemide and bumetanide can help people with PAH and heart failure.
Lung transplant: In severe cases, people with PAH may need a lung transplant.
New medications for pulmonary arterial hypertension
More medications are being developed to help treat PAH. In 2024, the FDA approved sotatercept for the treatment of PAH. A clinical trial found that people taking sotatercept could walk farther and had less shortness of breath with exercise.
Sotatercept works differently from other medications to treat PAH. It’s a fusion protein that binds to and traps some of the molecules that signal growth in the pulmonary arteries. Sotatercept helps prevent the walls of blood vessels from becoming thicker, which means there’s more room for blood flow.
What’s the prognosis like for someone with pulmonary arterial hypertension?
PAH is a serious, life-threatening condition. Symptoms typically get worse as the condition progresses. Prognosis refers to how healthcare professionals expect a condition to affect a person’s health over time. The prognosis for someone with PAH depends on several factors, including how severe symptoms are, the underlying cause of PAH, and their overall health.
Treatment can relieve symptoms and increase overall survival. Combination therapy (using more than one type of treatment) and new medications are improving prognosis for people with PAH.
Frequently asked questions
It depends on the cause of PAH, your age, underlying medical conditions, and the severity of the condition at the time of diagnosis. In the past, 1-, 5-, and 10-year survival rates for PAH (the percentage of people alive that many years after diagnosis) were 88%, 71%, and 35% respectively. But these numbers don’t take into account newer treatment options.
PAH can’t be diagnosed with spirometry, a lung function test that measures how well air flows into and out of the lungs. A diagnosis of PAH requires measuring the pressure inside the blood vessels in your lungs, which spirometry can’t assess.
The bottom line
PAH is a rare cause of pulmonary hypertension. It can cause fatigue, shortness of breath, and heart failure. There are several different types of PAH, each with different underlying causes. PAH can develop as a result of another condition or an inherited gene mutation. It can also happen without any clear cause. The prognosis for people with PAH is improving thanks to new medications.
Why trust our experts?
References
American Lung Association. (2023). Learn about pulmonary arterial hypertension.
Galiè, N., et al. (2015). Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine.
Ghofrani, H-A., et al. (2013). Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine.
Hansen, L., et al. (2018). Volume management in pulmonary arterial hypertension patients: An expert pulmonary hypertension clinician perspective. Pulmonary Therapy.
Hendriks, P. M., et al. (2022). The evolution of survival of pulmonary arterial hypertension over 15 years. Pulmonary Circulation.
Hoeper, M. M., (2023). Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. New England Journal of Medicine.
Humbert, M., et al. (2022). 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). European Heart Journal.
Kolaitis, N. A., et al. (2023). Lung transplantation for pulmonary arterial hypertension. Chest.
Lamb, K., et al. (2023). Spirometry. StatPearls.
Levine, D. J. (2021). Pulmonary arterial hypertension: Updates in epidemiology and evaluation of patients. American Journal of Managed Care.
Maron, B. A., et al. (2016). Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: A review. JAMA Cardiology.
McLaughlin, V. V., et al. (2004). Prognosis of pulmonary arterial hypertension. Chest.
Moles, V., et al. (2021). A novel therapeutic approach for the treatment of PAH: Results from PULSAR. American College of Cardiology.
National Organization for Rare Disorders. (2024). Pulmonary arterial hypertension.
Orcholski, M. E., et al. (2018). Drug-induced pulmonary arterial hypertension: A primer for clinicians and scientists. American Journal of Physiology. Lung Cellular and Molecular Physiology.
Perros, F., et al. (2015). Mitomycin-induced pulmonary veno-occlusive disease. Circulation.
Ramirez, R. L., et al. (2018). Methamphetamine and the risk of pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine.
Ryan, J. J., et al. (2012). The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulmonary Circulation.
ScienceDirect. (n.d.). Pulmonary capillary hemangiomatosis.
Siddiqui, N. A., et al. (2023). Pulmonary veno-occlusive disease. StatPearls.
